

# Primary Care Practice referrals to Monoclonal Antibody Infusions

- Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease
- mAbs are likely to be most beneficial if given to patients early in symptom progression
- Product delivered via single IV infusion administration
- Early evidence suggest promise of mAb products in **outpatient** settings to **reduce hospitalization**

## Process to refer your patients

### 1. Review patient eligibility criteria

*for patients with mild-moderate symptoms. Full criteria listed by FDA ([Bamlanivimab](#), [Casirivimab](#) and [Imdevimab](#)).*

### 2. Perform a COVID-19 PCR or Point-of-Care Rapid Antigen Test

*(POC Antigen Tests can be supplied by MDH: complete [this form](#) if interested).*

### 3. Refer your positive patients to a partnering infusion site\* ASAP

*to start treatment within 10 days of onset of symptoms.*

#### Option 1

Send an e-Referral via the CRISP Unified Landing Page ([Starter guide](#): pp. 1-7, 24-34)

OR

#### Option 2

Complete this [referral form](#) and submit directly to infusion site

## Adult Eligibility Criteria

At least 1 of the following:

1. BMI  $\geq 35$ ;
2. Chronic kidney disease;
3. Diabetes;
4. Immunosuppressive disease;
5. Receiving immunosuppressive treatment;
6. Age  $\geq 65$  years; OR
7. Age  $\geq 55$  years AND have any of the following:
  - Cardiovascular disease
  - Hypertension
  - COPD/other chronic respiratory disease

**\*As of 1/19/21, sites are as follows (in alphabetical order):** Adventist – Takoma Park, Atlantic General, Baltimore Convention Center Field Hospital, MedStar Southern Maryland, Meritus Health, Peninsula Regional-Tidal Health, UMPC